Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Rubio, M.J. (María Jesús) | - |
dc.creator | Lecumberri, M.J. (María José) | - |
dc.creator | Varela, S. (Silvia) | - |
dc.creator | Alarcón, J. (Jesús) | - |
dc.creator | Ortega, M.E. (María Eugenia) | - |
dc.creator | Gaba, L. (Lydia) | - |
dc.creator | Espinos, J. (Jaime) | - |
dc.creator | Calzas, J. (Julia) | - |
dc.creator | Barretina-Ginesta, P. (Pilar) | - |
dc.creator | Ruiz, I. (Isabel) | - |
dc.creator | Marquina, G. (Gloria) | - |
dc.creator | Santaballa, A. (Ana) | - |
dc.date.accessioned | 2023-05-16T11:10:47Z | - |
dc.date.available | 2023-05-16T11:10:47Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Rubio, M.J. (María Jesús); Lecumberri, M.J. (María José); Varela, S. (Silvia); et al. "Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)". Gynecologic Oncology Reports. 33 (100594), 2020, | es |
dc.identifier.issn | 2352-5789 | - |
dc.identifier.uri | https://hdl.handle.net/10171/66256 | - |
dc.description.abstract | Objective: We assessed trabectedin in patients with advanced uterine leiomyosarcoma (uLMS) in real-life clinical practice given according to the marketing authorization. Methods: Thirty-six women from 11 tertiary hospitals across Spain who received trabectedin after anthracyclinecontaining regimen/s were retrospectively analyzed. The primary endpoint was progression-free survival (PFS). Results: Median PFS and overall survival (OS) since starting trabectedin treatment were 5.4 (95%CI: 3.5–7.3) and 18.5 months (95%CI: 11.5–25.6), respectively. Median OS was significantly higher (P = 0.028) in patients receiving trabectedin in ≤ 2nd line (25.3 months) than in ≥ 3rd (15.1 months) and with ECOG performance status ≤ 1 at trabectedin start (19.8 months) than ECOG 2–3 (6.0 months, P = 0.013). When calculating OS since diagnosis, patients had longer OS with localized disease at diagnosis (87.4 months) vs. locally advanced (30.0 months) or metastatic (44.0 months, P = 0.041); and patients who received adjuvant therapy (87.4 months) compared with those who did not (30.0 months, P = 0.003), especially when receiving radiochemotherapy (106.7 months, P = 0.027). One patient (2.8%) had a complete response (CR) and nine patients (25.0%) achieved a partial response (PR) for an objective response rate of 27.8% with median response duration of 11 months (range: 4–93). Eighteen patients (50.0%) had disease stabilization for a disease control rate (DCR) of 77.8%. More patients receiving trabectedin in 1st-line of advanced disease achieved CR (16.7%) and PR (50.0%) than those in ≥ 2nd line/s (0.0% and 20.0%), whereas the DCR was similar across treatment lines. Reversible neutropenia was the most common grade 3/4 laboratory abnormality (19.4%). Conclusions: Trabectedin confers clinical benefit in patients with recurrent/metastatic uLMS, given after failure to an anthracycline-based regimen being comparable to those reported in clinical trials and with a manageable safety profile. | es_ES |
dc.description.sponsorship | This study was supported by funding from PharmaMar (Madrid, Spain). | es_ES |
dc.language.iso | eng | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Uterine leiomyosarcoma | es_ES |
dc.subject | Metastatic | es_ES |
dc.subject | Trabectedin | es_ES |
dc.subject | Efficacy | es_ES |
dc.subject | GEICO | es_ES |
dc.title | Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO) | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/). | es_ES |
dc.identifier.doi | 10.1016/j.gore.2020.100594 | - |
dadun.citation.number | 100594 | es_ES |
dadun.citation.publicationName | Gynecologic Oncology Reports | es_ES |
dadun.citation.volume | 33 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.